Entia Biosciences, Inc.
ERGO
$0.0001
-$0.0001-50.00%
| 12/31/2016 | 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | |
|---|---|---|---|---|---|
| Revenue | -32.75% | -38.38% | -8.97% | -22.58% | -77.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.75% | -38.38% | -8.97% | -22.58% | -77.30% |
| Cost of Revenue | -67.52% | -37.96% | -23.77% | 2.53% | -71.57% |
| Gross Profit | -3.75% | -38.92% | 2.28% | -33.80% | -80.56% |
| SG&A Expenses | 78.40% | -21.15% | -65.09% | -40.40% | -66.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.44% | -22.05% | -63.27% | -38.00% | -66.92% |
| Operating Income | -96.32% | 18.69% | 69.45% | 41.43% | 59.53% |
| Income Before Tax | -42.70% | 21.29% | 62.44% | 47.63% | 56.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.70% | 21.29% | 62.44% | 47.63% | 56.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.70% | 21.29% | 62.44% | 47.63% | 56.18% |
| EBIT | -96.32% | 18.69% | 69.45% | 41.43% | 59.53% |
| EBITDA | -102.56% | 18.30% | 69.67% | 41.33% | 60.29% |
| EPS Basic | -48.08% | 20.77% | 68.85% | 80.87% | 83.75% |
| Normalized Basic EPS | -107.32% | 22.89% | 75.18% | 80.44% | 86.42% |
| EPS Diluted | -48.08% | 20.77% | 68.85% | 80.87% | 83.75% |
| Normalized Diluted EPS | -107.32% | 22.89% | 75.18% | 80.44% | 86.42% |
| Average Basic Shares Outstanding | -3.33% | -0.63% | 20.67% | 173.73% | 169.32% |
| Average Diluted Shares Outstanding | -3.33% | -0.63% | 20.67% | 173.73% | 169.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
